AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 292: E829-E835, 2007. First published November 7, 2006; doi:10.1152/ajpendo.00133.2006
0193-1849/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/3/E829    most recent
00133.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Juurinen, L.
Right arrow Articles by Yki-Järvinen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Juurinen, L.
Right arrow Articles by Yki-Järvinen, H.

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

Leena Juurinen,1 Mirja Tiikkainen,1,4 Anna-Maija Häkkinen,2 Antti Hakkarainen,3 and Hannele Yki-Järvinen1

1Division of Diabetes, Department of Medicine, and 2Department of Oncology, 3Helsinki University of Technology, University of Helsinki, Helsinki; and 4Minerva Research Institute, Helsinki, Finland

Submitted 21 March 2006 ; accepted in final form 18 October 2006

We determined whether insulin therapy changes liver fat content (LFAT) or hepatic insulin sensitivity in type 2 diabetes. Fourteen patients with type 2 diabetes (age 51 ± 2 yr, body mass index 33.1 ± 1.4 kg/m2) treated with metformin alone received additional basal insulin for 7 mo. Liver fat (proton magnetic resonance spectroscopy), fat distribution (MRI), fat-free and fat mass, and whole body and hepatic insulin sensitivity (6-h euglycemic hyperinsulinemic clamp combined with infusion of [3-3H]glucose) were measured. The insulin dose averaged 75 ± 10 IU/day (0.69 ± 0.08 IU/kg, range 24–132 IU/day). Glycosylated hemoglobin A1c (Hb A1c) decreased from 8.9 ± 0.3 to 7.4 ± 0.2% (P < 0.001). Whole body insulin sensitivity increased from 2.21 ± 0.38 to 3.08 ± 0.40 mg/kg fat-free mass (FFM)·min (P < 0.05). This improvement could be attributed to enhanced suppression of hepatic glucose production (HGP) by insulin (HGP 1.04 ± 0.28 vs. 0.21 ± 0.19 mg/kg FFM·min, P < 0.01). The percent suppression of HGP by insulin increased from 72 ± 8 to 105 ± 11% (P < 0.01). LFAT decreased from 17 ± 3 to 14 ± 3% (P < 0.05). The change in LFAT was significantly correlated with that in hepatic insulin sensitivity (r = 0.56, P < 0.05). Body weight increased by 3.0 ± 1.1 kg (P < 0.05). Of this, 83% was due to an increase in fat-free mass (P < 0.01). Fat distribution and serum adiponectin concentrations remained unchanged while serum free fatty acids decreased significantly. Conclusions: insulin therapy improves hepatic insulin sensitivity and slightly but significantly reduces liver fat content, independent of serum adiponectin.

spectroscopy; steatosis; glucose



Address for reprint requests and other correspondence: H. Yki-Järvinen, Dept. of Medicine, Univ. of Helsinki, PO Box 700, FIN-00029 HUCH, Helsinki, Finland (e-mail: ykijarvi{at}cc.helsinki.fi)




This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
M. F-F Chong, L. Hodson, A. S Bickerton, R. Roberts, M. Neville, F. Karpe, K. N Frayn, and B. A Fielding
Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding
Am. J. Clinical Nutrition, April 1, 2008; 87(4): 817 - 823.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Kotronen and H. Yki-Jarvinen
Fatty Liver: A Novel Component of the Metabolic Syndrome
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 27 - 38.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
L. Hodson, A. S.T. Bickerton, S. E. McQuaid, R. Roberts, F. Karpe, K. N. Frayn, and B. A. Fielding
The Contribution of Splanchnic Fat to VLDL Triglyceride Is Greater in Insulin-Resistant Than Insulin-Sensitive Men and Women: Studies in the Postprandial State
Diabetes, October 1, 2007; 56(10): 2433 - 2441.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.